prednisone has been researched along with epothilone a in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| George, DJ; Moore, CN | 1 |
| Gross, M; Hussain, MH; Hutcheon, D; Kelly, WK; Michaelson, D; Rosenberg, JE; Small, EJ; Weinberg, VK; Wilding, G | 1 |
| Beer, TM; Harzstark, AL; Hussain, M; Mathew, P; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Ryan, CW; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK | 1 |
| Finter, F; Gust, K; Küfer, R; Rinnab, L | 1 |
| Feng, J; Liu, CW; Luo, XH; Wang, HF; Zhang, XZ; Zhuo, RX | 1 |
| Alonso, M; Beer, TM; Giurescu, M; Hussain, A; Roth, K; Smith, DC; Wang, J; Wang, Y | 1 |
| Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK | 1 |
| Broccoli, A; Casadei, B; Derenzini, E; Gandolfi, L; Pellegrini, C; Zinzani, PL | 1 |
2 review(s) available for prednisone and epothilone a
| Article | Year |
|---|---|
Update in the management of patients with hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agonists; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epothilones; Estramustine; Humans; Male; Mitoxantrone; Multicenter Studies as Topic; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
[Palliative systemic therapy of castration-resistant prostate cancer: current developments].
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Epothilones; Evidence-Based Medicine; Humans; Immunotherapy; Male; Neoplasm Staging; Orchiectomy; Palliative Care; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Tubulin Modulators | 2009 |
3 trial(s) available for prednisone and epothilone a
| Article | Year |
|---|---|
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Epothilones; Humans; Male; Middle Aged; Orchiectomy; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms | 2012 |
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epothilones; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
3 other study(ies) available for prednisone and epothilone a
| Article | Year |
|---|---|
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Epothilones; Humans; Infusions, Subcutaneous; Male; Middle Aged; Military Personnel; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2009 |
A smart micellar system with an amine-containing polycarbonate shell.
Topics: Amines; Calorimetry, Differential Scanning; Cell Death; Cell Survival; Epothilones; Fluorescence; HEK293 Cells; HeLa Cells; Humans; Hydrodynamics; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Light; Magnetic Resonance Spectroscopy; Micelles; Microscopy, Electron, Transmission; Polycarboxylate Cement; Polyesters; Polymerization; Prednisone; Scattering, Radiation; Temperature; Water | 2012 |
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epothilones; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisone; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |